AI English summary of an SEC filing — figures as filed
Abbott Laboratories ABTThe company said net sales for Q3 2025 (quarter ended September 30) rose to $11,369 million, up 6.9% from $10,635 million a year earlier. Organic sales growth was 5.5%, or 7.5% excluding COVID-19 testing-related sales.
Key points
AI summaryThe company said net sales for Q3 2025 (quarter ended September 30) rose to $11,369 million, up 6.9% from $10,635 million a year earlier. Organic sales growth was 5.5%, or 7.5% excluding COVID-19 testing-related sales.
Abbott said GAAP diluted EPS for Q3 was $0.94, flat with the prior-year quarter, while adjusted diluted EPS excluding specified items was $1.30, up 7.4% from $1.21 a year earlier. The effective tax rate for Q3 was $536 million.
The company said Medical Devices sales for Q3 rose 14.8% on a reported basis to $5,448 million, while Diagnostics sales fell 6.6% to $2,253 million. It said COVID-19 testing-related sales were $69 million, compared with $265 million a year earlier.
The company reaffirmed its 2025 full-year organic sales growth guidance of 7.5% to 8.0% excluding COVID-19 testing-related sales, or 6.0% to 7.0% including them. It kept the midpoint of its adjusted diluted EPS guidance and narrowed the range to $5.12 to $5.18.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Net sales of $11,369 million in Q3, up 6.9% as reported
The company said net sales for Q3 2025 (quarter ended September 30) rose to $11,369 million, up 6.9% from $10,635 million a year earlier. Organic sales growth was 5.5%, or 7.5% excluding COVID-19 testing-related sales.
Source · Based on the filing body and exhibits
Q3 GAAP diluted EPS $0.94, adjusted EPS $1.30
Abbott said GAAP diluted EPS for Q3 was $0.94, flat with the prior-year quarter, while adjusted diluted EPS excluding specified items was $1.30, up 7.4% from $1.21 a year earlier. The effective tax rate for Q3 was $536 million.
Source · Based on the filing body and exhibits
Medical Devices up 14.8%, Diagnostics down 6.6%
The company said Medical Devices sales for Q3 rose 14.8% on a reported basis to $5,448 million, while Diagnostics sales fell 6.6% to $2,253 million. It said COVID-19 testing-related sales were $69 million, compared with $265 million a year earlier.
Source · Based on the filing body and exhibits
Full-year outlook: organic sales growth reaffirmed, adjusted EPS range narrowed
The company reaffirmed its 2025 full-year organic sales growth guidance of 7.5% to 8.0% excluding COVID-19 testing-related sales, or 6.0% to 7.0% including them. It kept the midpoint of its adjusted diluted EPS guidance and narrowed the range to $5.12 to $5.18.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…